Church M W, Subramanian M G
Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Am J Obstet Gynecol. 1997 Apr;176(4):901-6. doi: 10.1016/s0002-9378(97)70619-7.
Cocaine-associated morbidities in pregnant women (e.g., abruptio placentae, hypertension, seizures) occur mostly during the final stages of gestation. The purpose of our study was to determine whether cocaine's toxicity and blood levels varied as a function of "critical periods" of exposure during gestation.
To evaluate mortality rates, pregnant Long-Evans rats received subcutaneously 30, 40, or 50 mg/kg cocaine hydrochloride twice daily (C30, C40, and C50 groups) either during gestational days 7 to 13 (midgestation) or gestational days 14 to 20 (late gestation) (n 9 to 20 per group). Serum levels of the cocaine metabolite benzoylecgonine were examined in other groups of rats on either gestational day 13 (mid) or day 20 (late) in the C30 treatment condition (n = 5 and 10 per group).
There were no maternal mortalities in the midgestation groups at any dose. In contrast, the late-gestation groups showed a dramatic dose-dependent effect, with maternal mortality rates of 0%, 40%, and 72% in the C30, C40, and C50 groups. The late-gestation group had higher benzoylecgonine levels than the midgestation groups did.
Late gestation was associated with higher maternal mortality rates and higher benzoylecgonine levels, indicating that some underlying physiologic change enhanced cocaine's toxicity as pregnancy progressed. This increased sensitivity to cocaine may be mediated by estrogen or progesterone, suggesting that the cocaine-abusing woman is at increased risk for cocaine-induced morbidities whenever levels of these hormones are elevated, such as during the final stages of pregnancy or possibly when taking oral contraceptives.
孕妇与可卡因相关的并发症(如胎盘早剥、高血压、癫痫发作)大多发生在妊娠后期。我们研究的目的是确定可卡因的毒性和血药浓度是否会随着孕期“关键时期”的暴露而变化。
为了评估死亡率,将怀孕的Long-Evans大鼠在妊娠第7至13天(妊娠中期)或妊娠第14至20天(妊娠后期)每天皮下注射两次30、40或50mg/kg盐酸可卡因(C30、C40和C50组)(每组n = 9至20)。在C30治疗条件下,于妊娠第13天(中期)或第20天(后期)检测其他组大鼠血清中可卡因代谢物苯甲酰爱康宁的水平(每组n = 5和10)。
妊娠中期组无论何种剂量均无母体死亡。相比之下,妊娠后期组呈现出显著的剂量依赖性效应,C30、C40和C50组的母体死亡率分别为0%、40%和72%。妊娠后期组的苯甲酰爱康宁水平高于妊娠中期组。
妊娠后期与较高的母体死亡率和较高的苯甲酰爱康宁水平相关,表明随着妊娠进展,某些潜在的生理变化增强了可卡因的毒性。对可卡因敏感性的增加可能由雌激素或孕酮介导,这表明滥用可卡因的女性在这些激素水平升高时,如妊娠后期或可能在服用口服避孕药时,发生可卡因诱发并发症的风险会增加。